Idorsia Says FDA Grants Breakthrough Designation to Daridorexant for Pediatric Insomnia
The designation covers patients aged 10 to under 18 and follows a short Phase 2 study. The company reports a sleep-time signal, but the full dataset remains under journal review and pediatric use is still investigational.
7 min read ↗